Uruguayan experience with cryopreserved arterial homografts

A. Esperon, E. Kamaid, M. Diamant, H.P. Campos, M. Del Carmen Saldias, A. Icasuriaga, C. Varela, D. Delgado, I. Alvarez

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

INTRODUCTION: We analyzed the Uruguayan experience with cryopreserved arterial homografts. We studied 55 medical records in the period from June 9, 2000 to April 7, 2007, including 41 from males and 14 from females, ranging from 36-78 years of age. The clinical indications were as follows: Group 1, revascularization of infrainguinal atherosclerotic occlusive disease by bypass due to the lack of availability of a suitable vein (n = 35); Group 2, substitution of an infected prosthetic grafts (n = 15); and Group 3, arteriovenous fistula (AVF) after failure of previous prosthetic loops by repeated thrombosis and/or infection in the absence of a vein (n = 5). RESULTS: Among Group 1, primary and secondary patency rates were 61% and 71%, respectively at 1 year with 15 complications, 3 infections, 8 thromboses, 2 aneurysms, 1 homograft degradation, and 1 death related to surgery. Among Group 2, the primary and secondary patency rates were 71% and 79%, respectively, at 1 year with 6 patients experiencing complications. Group 3 did not have complications with a primary patency rate of 67% at 1 year. CONCLUSIONS: The use of cryopreserved arterial homografts is a valid, accessible, and safe alternative in complicated vascular situations. In our country, it is a technology to consider for patients with critical limb ischemia, when the risk of a major amputation is high and it is not possible to have a suitable vein or prosthetic bypass. It can be an excellent alternative for the substitution of infected synthetic bypasses, especially to substitute in situ for an infected aortic graft
Original languageUndefined/Unknown
Pages (from-to)3500-3504
JournalTransplantation Proceedings
Volume41
Issue number8
DOIs
Publication statusPublished - 2009

Cite this

Esperon, A., Kamaid, E., Diamant, M., Campos, H. P., Del Carmen Saldias, M., Icasuriaga, A., ... Alvarez, I. (2009). Uruguayan experience with cryopreserved arterial homografts. Transplantation Proceedings, 41(8), 3500-3504. https://doi.org/10.1016/j.transproceed.2009.09.006
Esperon, A. ; Kamaid, E. ; Diamant, M. ; Campos, H.P. ; Del Carmen Saldias, M. ; Icasuriaga, A. ; Varela, C. ; Delgado, D. ; Alvarez, I. / Uruguayan experience with cryopreserved arterial homografts. In: Transplantation Proceedings. 2009 ; Vol. 41, No. 8. pp. 3500-3504.
@article{f70dd7e080074f0495af94720081dcb2,
title = "Uruguayan experience with cryopreserved arterial homografts",
abstract = "INTRODUCTION: We analyzed the Uruguayan experience with cryopreserved arterial homografts. We studied 55 medical records in the period from June 9, 2000 to April 7, 2007, including 41 from males and 14 from females, ranging from 36-78 years of age. The clinical indications were as follows: Group 1, revascularization of infrainguinal atherosclerotic occlusive disease by bypass due to the lack of availability of a suitable vein (n = 35); Group 2, substitution of an infected prosthetic grafts (n = 15); and Group 3, arteriovenous fistula (AVF) after failure of previous prosthetic loops by repeated thrombosis and/or infection in the absence of a vein (n = 5). RESULTS: Among Group 1, primary and secondary patency rates were 61{\%} and 71{\%}, respectively at 1 year with 15 complications, 3 infections, 8 thromboses, 2 aneurysms, 1 homograft degradation, and 1 death related to surgery. Among Group 2, the primary and secondary patency rates were 71{\%} and 79{\%}, respectively, at 1 year with 6 patients experiencing complications. Group 3 did not have complications with a primary patency rate of 67{\%} at 1 year. CONCLUSIONS: The use of cryopreserved arterial homografts is a valid, accessible, and safe alternative in complicated vascular situations. In our country, it is a technology to consider for patients with critical limb ischemia, when the risk of a major amputation is high and it is not possible to have a suitable vein or prosthetic bypass. It can be an excellent alternative for the substitution of infected synthetic bypasses, especially to substitute in situ for an infected aortic graft",
author = "A. Esperon and E. Kamaid and M. Diamant and H.P. Campos and {Del Carmen Saldias}, M. and A. Icasuriaga and C. Varela and D. Delgado and I. Alvarez",
year = "2009",
doi = "10.1016/j.transproceed.2009.09.006",
language = "Undefined/Unknown",
volume = "41",
pages = "3500--3504",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "8",

}

Esperon, A, Kamaid, E, Diamant, M, Campos, HP, Del Carmen Saldias, M, Icasuriaga, A, Varela, C, Delgado, D & Alvarez, I 2009, 'Uruguayan experience with cryopreserved arterial homografts' Transplantation Proceedings, vol. 41, no. 8, pp. 3500-3504. https://doi.org/10.1016/j.transproceed.2009.09.006

Uruguayan experience with cryopreserved arterial homografts. / Esperon, A.; Kamaid, E.; Diamant, M.; Campos, H.P.; Del Carmen Saldias, M.; Icasuriaga, A.; Varela, C.; Delgado, D.; Alvarez, I.

In: Transplantation Proceedings, Vol. 41, No. 8, 2009, p. 3500-3504.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Uruguayan experience with cryopreserved arterial homografts

AU - Esperon, A.

AU - Kamaid, E.

AU - Diamant, M.

AU - Campos, H.P.

AU - Del Carmen Saldias, M.

AU - Icasuriaga, A.

AU - Varela, C.

AU - Delgado, D.

AU - Alvarez, I.

PY - 2009

Y1 - 2009

N2 - INTRODUCTION: We analyzed the Uruguayan experience with cryopreserved arterial homografts. We studied 55 medical records in the period from June 9, 2000 to April 7, 2007, including 41 from males and 14 from females, ranging from 36-78 years of age. The clinical indications were as follows: Group 1, revascularization of infrainguinal atherosclerotic occlusive disease by bypass due to the lack of availability of a suitable vein (n = 35); Group 2, substitution of an infected prosthetic grafts (n = 15); and Group 3, arteriovenous fistula (AVF) after failure of previous prosthetic loops by repeated thrombosis and/or infection in the absence of a vein (n = 5). RESULTS: Among Group 1, primary and secondary patency rates were 61% and 71%, respectively at 1 year with 15 complications, 3 infections, 8 thromboses, 2 aneurysms, 1 homograft degradation, and 1 death related to surgery. Among Group 2, the primary and secondary patency rates were 71% and 79%, respectively, at 1 year with 6 patients experiencing complications. Group 3 did not have complications with a primary patency rate of 67% at 1 year. CONCLUSIONS: The use of cryopreserved arterial homografts is a valid, accessible, and safe alternative in complicated vascular situations. In our country, it is a technology to consider for patients with critical limb ischemia, when the risk of a major amputation is high and it is not possible to have a suitable vein or prosthetic bypass. It can be an excellent alternative for the substitution of infected synthetic bypasses, especially to substitute in situ for an infected aortic graft

AB - INTRODUCTION: We analyzed the Uruguayan experience with cryopreserved arterial homografts. We studied 55 medical records in the period from June 9, 2000 to April 7, 2007, including 41 from males and 14 from females, ranging from 36-78 years of age. The clinical indications were as follows: Group 1, revascularization of infrainguinal atherosclerotic occlusive disease by bypass due to the lack of availability of a suitable vein (n = 35); Group 2, substitution of an infected prosthetic grafts (n = 15); and Group 3, arteriovenous fistula (AVF) after failure of previous prosthetic loops by repeated thrombosis and/or infection in the absence of a vein (n = 5). RESULTS: Among Group 1, primary and secondary patency rates were 61% and 71%, respectively at 1 year with 15 complications, 3 infections, 8 thromboses, 2 aneurysms, 1 homograft degradation, and 1 death related to surgery. Among Group 2, the primary and secondary patency rates were 71% and 79%, respectively, at 1 year with 6 patients experiencing complications. Group 3 did not have complications with a primary patency rate of 67% at 1 year. CONCLUSIONS: The use of cryopreserved arterial homografts is a valid, accessible, and safe alternative in complicated vascular situations. In our country, it is a technology to consider for patients with critical limb ischemia, when the risk of a major amputation is high and it is not possible to have a suitable vein or prosthetic bypass. It can be an excellent alternative for the substitution of infected synthetic bypasses, especially to substitute in situ for an infected aortic graft

U2 - 10.1016/j.transproceed.2009.09.006

DO - 10.1016/j.transproceed.2009.09.006

M3 - Article

VL - 41

SP - 3500

EP - 3504

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 8

ER -

Esperon A, Kamaid E, Diamant M, Campos HP, Del Carmen Saldias M, Icasuriaga A et al. Uruguayan experience with cryopreserved arterial homografts. Transplantation Proceedings. 2009;41(8):3500-3504. https://doi.org/10.1016/j.transproceed.2009.09.006